Ketamine is a novel and rapidly acting treatment for major depressive disorder (MDD). Benzodiazepines are commonly coprescribed with antidepressants in MDD. This study sought to examine data from a randomized clinical trial that compared a single infusion of intravenous (IV) ketamine to midazolam placebo in treatment-resistant depression ( MDD) and to assess whether the use of concomitant oral benzodiazepines differentially affected treatment response to ketamine versus midazolam. This trial ran from December 2015 to December 2016. Subjects who were taking oral benzodiazepines (n = 44) were compared to those who were not (n = 55). A significant treatment-by-benzodiazepine effect could be interpreted as a possible moderator of differential treatment response to ketamine versus midazolam. Benzodiazepine use was examined as both a binary and a continuous predictor, to assess the impact of dosage. Benzodiazepine users did not differ from non-users on the original study's primary outcome measure, score on the 6-item Hamilton Depression Rating Scale (HDRS-6), at baseline, but the former had more severe anxiety. When oral benzodiazepine use was modeled as a binary predictor, benzodiazepine use did not impact differential treatment response. However, when benzodiazepine dosage was considered, there was a significant impact of benzodiazepine use on differential treatment response. Oral benzodiazepines significantly impacted HDRS-6 ( = .018) and Clinical Global Impressions-Severity of Illness scale (CGI-S; = .008) scores at day 1 (24 hours post treatment); effects were nonsignificant for all day 3 outcomes. Among ketamine subjects, higher doses of benzodiazepines were associated with less improvement in depression scores at day 1. Concomitant oral benzodiazepines at higher doses may attenuate the antidepressant effects of IV ketamine at day 1 but not day 3 post-infusion. ClinicalTrials.gov identifier: NCT01920555.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.4088/JCP.22m14491 | DOI Listing |
J Oral Facial Pain Headache
June 2024
Research Institute of Clinical Medicine of Jeonbuk National University-Biomedical Research Institute of Jeonbuk National University Hospital, 54907 Jeonju-si, Republic of Korea.
There is a lack of objective indicators to evaluate the treatment effect of burning mouth syndrome, a neuropathic pain of unknown causes. Therefore, this study aimed to evaluate potential salivary biomarkers by analyzing saliva before and after clonazepam treatment in patients with burning mouth syndrome. Saliva was collected from 23 patients with burning mouth syndrome before and 4 weeks after the topical administration of clonazepam.
View Article and Find Full Text PDFNeuropsychopharmacol Hung
December 2024
College of Medicine, University of Kentucky, Lexington, KY 40506, USA.
Objective: Benzodiazepines, particularly lorazepam, are good options for acute catatonia treatment. Published catatonia literature on benzodiazepine maintenance treatment and benzodiazepine tolerance is limited.
Methods: This is a chart review covering 30 years of clinical experience in the state of Kentucky, (United States of America), where there was no easy access to electroconvulsive therapy.
Front Psychiatry
December 2024
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (FMUSP), Instituto de Psiquiatria, São Paulo, Brazil.
Objective: This study presents a case series of five women with zolpidem dependence treated at the Drug Dependent Women Treatment Center (PROMUD), one of the first women-specific substance use disorder outpatient services in Latin America.
Methods: This was an retrospective review of medical records of patients with a diagnosis of zolpidem dependence at the Institute of Psychiatry of Clinics Hospital of University of São Paulo between December 2021 and December 2023. Description of the cases followed the Case Report Statement, Checklist and Guidelines (CARE).
Drug Des Devel Ther
December 2024
Anesthesia Surgical Center, The First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, People's Republic of China.
Purpose: To evaluate the efficacy and safety of intranasal dexmedetomidine (Dex), oral lorazepam, and a placebo in managing preoperative anxiety-related insomnia.
Patients And Methods: A total of 90 patients exhibiting symptoms of preoperative anxiety and insomnia were randomly assigned to three groups: Dex (receiving 2.5 µg/kg Dex intranasally and starch tablets orally), lorazepam (receiving saline intranasally and 2 mg lorazepam orally), and placebo (receiving saline intranasally and starch tablets orally).
BMC Oral Health
December 2024
Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Chiba, Noda, 278-8510, Japan.
Background: With the rise in the older population, it has become important to understand the relationship between oral frailty and drug use to consider appropriate medical interventions and drug use for older persons.
Objective: To clarify the relationship among oral frailty, drug use, and other patient backgrounds and to identify relevant factors using information from patient questionnaires and pharmacy medication history records.
Methods: This cross-sectional study involved community-dwelling older adults.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!